$25.03−$0.3200 (−1.26%) on the dayAs of the close; data may be delayed.
STAA price, last 12 months
$33.34$16.10$25.03
Daily closes over the last 260 trading sessions: −5.7%. Highest close $33.34 on , lowest $16.10 on . Market data may be delayed.
Key stats
Previous close
$25.35
Open
$25.19
Day range
$24.77 – $25.93
52-week range
$15.59 – $35.87
Volume
557.8K
Avg volume (20 days)
788.6K
Market cap
$1.3B
Performance
1W−8.2%
1M+7.7%
3M+4.1%
6M−25.4%
YTD+4.9%
1Y−8.4%
vs S&P 500, 1Y−13.7 pts
Technicals and fundamentals
About Staar Surgical Co
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
Chart STAA with indicators, scan for setups and get alerts
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
A full STAA chart with indicator overlays, pattern markers and daily, weekly or intraday bars.
Scans of a whole index or list with 72 named conditions, 26 chart setups or a formula of your own.
Alerts and notifications when one fires on a stock you watch, on delayed market data.
Daily range (ATR)5.0%average true range, % of price
52w low $15.5952w high $35.87
Where price sits today against its own history. A description, not a forecast.
Valuation
P/E (trailing)2,292.2104.62x Manufacturing median (21.9)
P/E (forward)21.4
PEG0.76
Price / sales3.70
Price / book3.23
EV / EBITDA—
P/E since Jun 1251.1 – 2,595.7
Company figures as of Nov 20, 2026.
Analysts
ConsensusBuy2.5 on 1 (strong buy) to 5 (strong sell)
Analysts9
Average target$28.56+17.9% from today
Price targets are opinions and tend to lean optimistic.
Earnings
Next results, expectedaround Mar 2, 2027 (in 101 days)A year after its Mar 3, 2026 results release; the last came Nov 4, 2026. An estimate from its SEC filings, not a date the company announced.
Seasonality
-0.7
J
-4.7
F
+6.7
M
+9.3
A
-0.2
M
+0.6
J
-0.8
J
+4.4
A
-4.4
S
-3.4
O
-12.2
N
-9.8
D
Average return in each calendar month, Oct 31, 2021 to Oct 31, 2026. 6 years is 6 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
Year by year
Year
J
F
M
A
M
J
J
A
S
O
N
D
Year
2026
−18
+5
−6
+41
+13
−4
−15
−7
+0
+9
+6%
2025
−0
−28
+1
+4
−2
−6
+7
+53
−2
−4
+3
−13
−5%
2024
−10
+12
+23
+20
−10
+15
−13
−20
+12
−22
+0
−17
−22%
2023
+45
−21
+15
+10
−18
−9
+4
−21
−7
+4
−25
−0
−36%
2022
−20
+9
+1
−29
+16
+8
+14
+17
−25
+0
−19
−15
−47%
2021
−8
−20
−4
−29%
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
Financials
As reported in the company's SEC filings. Latest: Q3 FY2026, ended Oct 2, 2026.
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
Analyst upgrade from hold to buy with raised price target, positive sales momentum expected in H2 2026, strong market position in China, and recognition as potential acquisition target for larger healthcare companies
The company announced a substantial $50 million share buyback program, demonstrating management confidence in undervaluation. Strong Q2 fundamentals including doubled net sales year-over-year, return to profitability, and robust cash position of $149 million support the positive outlook. Market responded favorably with 7.5% stock price increase.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.